Evidence map›Paper›PMID 31830004›Full record

ArticleJCI insight2020

Structure-function relationships of HDL in diabetes and coronary heart disease.

Mathias Cardner, Mustafa Yalcinkaya, Sandra Goetze, Edlira Luca, Miroslav Balaz, Monika Hunjadi, Johannes Hartung, Andrej Shemet, Nicolle Kränkel, Silvija Radosavljevic and 15 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. HDL metabolism and function in diabetes mellitus.Nature reviews. Endocrinology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 4 countries.

Mathias CardnerDepartment of Biosystems Science and Engineering, Swiss Federal Institute of Technology in Zurich (ETH Zurich), Basel, Switzerland.
Mustafa YalcinkayaInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Sandra GoetzeDepartment of Health Sciences and Technology and.
Edlira LucaDepartment of Diabetology and Endocrinology, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Miroslav BalazDepartment of Health Sciences and Technology and.
Monika HunjadiDepartment of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Johannes HartungDepartment of Cardiology, University Medicine Charité Berlin, Berlin, Germany.
Andrej ShemetDepartment of Chemistry and Applied Biosciences and.
Nicolle KränkelDepartment of Cardiology, University Medicine Charité Berlin, Berlin, Germany.
Silvija RadosavljevicInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Michaela KeelInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Alaa OthmanInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Gergely KarsaiInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Thorsten HornemannInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Manfred ClaassenInstitute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
Gerhard LiebischInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Erick CarreiraDepartment of Chemistry and Applied Biosciences and.
Andreas RitschDepartment of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Ulf LandmesserDepartment of Cardiology, University Medicine Charité Berlin, Berlin, Germany.
Jan KrützfeldtDepartment of Diabetology and Endocrinology, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Christian WolfrumDepartment of Health Sciences and Technology and.
Bernd WollscheidDepartment of Health Sciences and Technology and.
Niko BeerenwinkelDepartment of Biosystems Science and Engineering, Swiss Federal Institute of Technology in Zurich (ETH Zurich), Basel, Switzerland.
Lucia RohrerInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
Arnold von EckardsteinInstitute of Clinical Chemistry, University of Zurich and University Hospital of Zurich, Zurich, Switzerland.
University of Zurich · CHCharité - Universitätsmedizin Berlin · DEETH Zurich · CHDepartment of Medical Sciences · BYInnsbruck Medical University · ATSIB Swiss Institute of Bioinformatics · CHUniversity Hospital of Zurich · CHUniversity Hospital Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-density lipoproteins (HDL) contain hundreds of lipid species and proteins and exert many potentially vasoprotective and antidiabetogenic activities on cells. To resolve structure-function-disease relationships of HDL, we characterized HDL of 51 healthy subjects and 98 patients with diabetes (T2DM), coronary heart disease (CHD), or both for protein and lipid composition, as well as functionality in 5 cell types. The integration of 40 clinical characteristics, 34 nuclear magnetic resonance (NMR) features, 182 proteins, 227 lipid species, and 12 functional read-outs by high-dimensional statistical modeling revealed, first, that CHD and T2DM are associated with different changes of HDL in size distribution, protein and lipid composition, and function. Second, different cellular functions of HDL are weakly correlated with each other and determined by different structural components. Cholesterol efflux capacity (CEC) was no proxy of other functions. Third, 3 potentially novel determinants of HDL function were identified and validated by the use of artificially reconstituted HDL, namely the sphingadienine-based sphingomyelin SM 42:3 and glycosylphosphatidylinositol-phospholipase D1 for the ability of HDL to inhibit starvation-induced apoptosis of human aortic endothelial cells and apolipoprotein F for the ability of HDL to promote maximal respiration of brown adipocytes.

Indexed as

AtherosclerosisBiological AssayCoronary DiseaseDiabetes MellitusDiabetes Mellitus, Type 2HumansLipidomicsLipoproteinsLipoproteins, HDLMaleProteomicsStructure-Activity RelationshipLipoproteinsLipoproteins, HDLAtherosclerosisCardiologyDiabetesLipoproteinsMetabolism

Identifiers

PMID31830004
PMCPMC7030825
OpenAlexW2998027588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.